Literature DB >> 34061824

Association of APOE ε4 genotype and lifestyle with cognitive function among Chinese adults aged 80 years and older: A cross-sectional study.

Xurui Jin1,2, Wanying He1, Yan Zhang1, Enying Gong3, Zhangming Niu2, John Ji4, Yaxi Li1, Yi Zeng5,6,7, Lijing L Yan1,5,8,9,10.   

Abstract

BACKGROUND: Apolipoprotein E (APOE) ε4 is the single most important genetic risk factor for cognitive impairment and Alzheimer disease (AD), while lifestyle factors such as smoking, drinking, diet, and physical activity also have impact on cognition. The goal of the study is to investigate whether the association between lifestyle and cognition varies by APOE genotype among the oldest old. METHODS AND
FINDINGS: We used the cross-sectional data including 6,160 oldest old (aged 80 years old or older) from the genetic substudy of the Chinese Longitudinal Healthy Longevity Survey (CLHLS) which is a national wide cohort study that began in 1998 with follow-up surveys every 2-3 years. Cognitive impairment was defined as a Mini-Mental State Examination (MMSE) score less than 18. Healthy lifestyle profile was classified into 3 groups by a composite measure including smoking, alcohol consumption, dietary pattern, physical activity, and body weight. APOE genotype was categorized as APOE ε4 carriers versus noncarriers. We examined the associations of cognitive impairment with lifestyle profile and APOE genotype using multivariable logistic regressions, controlling for age, sex, education, marital status, residence, disability, and numbers of chronic conditions. The mean age of our study sample was 90.1 (standard deviation [SD], 7.2) years (range 80-113); 57.6% were women, and 17.5% were APOE ε4 carriers. The mean MMSE score was 21.4 (SD: 9.2), and 25.0% had cognitive impairment. Compared with those with an unhealthy lifestyle, participants with intermediate and healthy lifestyle profiles were associated with 28% (95% confidence interval [CI]: 16%-38%, P < 0.001) and 55% (95% CI: 44%-64%, P < 0.001) lower adjusted odds of cognitive impairment. Carrying the APOE ε4 allele was associated with 17% higher odds (95% CI: 1%-31%, P = 0.042) of being cognitively impaired in the adjusted model. The association between lifestyle profiles and cognitive function did not vary significantly by APOE ε4 genotype (noncarriers: 0.47 [0.37-0.60] healthy versus unhealthy; carriers: 0.33 [0.18-0.58], P for interaction = 0.30). The main limitation was the lifestyle measurements were self-reported and were nonspecific. Generalizability of the findings is another limitation because the study sample was from the oldest old in China, with unique characteristics such as low body weight compared to populations in high-income countries.
CONCLUSIONS: In this study, we observed that healthier lifestyle was associated with better cognitive function among the oldest old regardless of APOE genotype. Our findings may inform the cognitive outlook for those oldest old with high genetic risk of cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34061824      PMCID: PMC8168868          DOI: 10.1371/journal.pmed.1003597

Source DB:  PubMed          Journal:  PLoS Med        ISSN: 1549-1277            Impact factor:   11.613


Introduction

Genetic profile and lifestyle factors are both associated with cognitive function [1,2]. Among various genetic factors, the apolipoprotein E (APOE) ε4 allele is the most significant one, accounting for about 5% of the variance in lifetime cognitive decline and 4% of the variance in Alzheimer disease (AD) [3]. APOE is associated with the clearance rate of amyloid beta, which is a hallmark of AD, and the presence of the ε4 allele indicates a slower clearance rate [4]. The influence of modifiable lifestyle factors on cognition has been demonstrated in many studies [5-7]. Prior studies have proved that a healthier lifestyle characterized by abstaining from smoking or drinking, adhering to regular physical activity, and a healthy dietary pattern was associated with a low incidence of cognitive impairment [5,8-10]. However, most previous research examined single lifestyle factors; only a few studies investigated the impact of combined lifestyle profile on cognition. For instance, a study that included 977 Korean adults aged over 65 years old demonstrated that a healthier lifestyle profile was associated with a lower rate of cognitive decline [11]. In addition, an incremental benefit of multiple lifestyle behaviors was observed. But it is still unclear how a healthy lifestyle may contribute to the cognitive function among those oldest old (aged 80 years old or older), who represent the fastest-growing segment of populations worldwide. Whether the effect of lifestyle on cognition varies by genetic dementia risk represented by different APOE genotypes is still unclear. Prior research reported inconsistent results on the interactions between APOE genotype and lifestyle factors on cognitive outcomes. Some studies found significant interactions between APOE genotype and single lifestyle factors, such as physical activity [12], alcohol consumption [13], and diet [14], or the combined effect of lifestyle factors [8], with stronger effects among APOE ε4 carriers than noncarriers. However, other studies failed to detect such an interaction [9]. All of these studies were conducted among middle-aged adults or older adults mostly under 80 years old. We used the genetic substudy from the Chinese Longitudinal Healthy Longevity Survey (CLHLS), a large-scale community-based study, to examine whether APOE genotype interacts with the relationship between a combined lifestyle profile, including smoking, alcohol consumption, physical activity, dietary pattern, and body weight, with cognitive function among the oldest old in China. Together with other studies and evidence from interventional trials, the goal of our study is to shed light on potential health intervention strategies to improve cognitive functioning in older age, including the oldest old—the fastest-growing segment of our population.

Methods

Study design and sample

The present study uses data from the CLHLS, which is an ongoing longitudinal study that began in 1998 with follow-up surveys every 2 to 3 years. The CLHLS is a Chinese nationwide survey conducted in randomly selected counties and cities in 22 out of 30 provinces covering 85% of China’s population. All centenarians from the selected areas who agreed to participate were included in the study. Based on sex and place of residence (i.e., living in the same street, village, city, or county) for a given centenarian, randomly selected octogenarians and nonagenarians were also sampled. More details about the sampling procedure and quality of data of this survey have been published elsewhere [15]. Ethics approval was obtained from the Research Ethics Committees of Peking University and Duke University (IRB00001052-13074). All participants or their legal representatives signed written consent forms in the baseline and follow-up surveys. In this cross-sectional analysis, we pooled baseline data from all CLHLS surveys conducted between 1998 and 2014 that included genetic and lifestyle assessment, and this study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (S1 Checklist). The CLHLS genetic substudy had a total of 6,399 participants aged over 80 years or older. After excluding those participants with missing value for APOE genotyping (rs429358 or rs7412) (N = 133) or missing value in Mini-Mental State Examination (MMSE) or lifestyle measurements (N = 106; MMSE: 51, lifestyle factors: 55), we included 6,160 participants aged 80 or above in our analyses.

APOE genotyping

Saliva samples were collected from participants in 6 waves of CLHLS (1998, 2000, 2002, 2005, 2008, and 2011), and the genotyping was performed in 2014 by Beijing Genomics Institute (BGI). A customized chip targeting about 27K longevity phenotype–related SNPs was used, and the BGI genotyping quality control procedure of the CLHLS genetics study is published elsewhere [16]. We extracted rs429358 and rs7412 to determine APOE genotype and further grouped all study participants by carrying the APOE ε4 allele (ε2/ε4, ε3/ε4, ε4/ε4 genotypes) or not (ε2/ε2, ε2/ε3, ε3/ε3 genotypes) [17].

Assessment of healthy lifestyle

The data were collected through face-to-face interviews by trained interviewers who are local staff members from the county-level network system of the National Bureau of Statistics of China. All interviewers have received 12+ years of schooling, and most have earned a college degree. Each interviewer was accompanied by a local doctor, a nurse, or a medical college student so that some health checkups could be performed. In the physical examination, body weight and height were measured by trained medical staff using a standardized protocol. Survey questions from CLHLS were presented in S3 Text. The healthy lifestyle score was constructed by collecting information on smoking, alcohol consumption, physical activity, dietary pattern, and body weight. The smoking status was categorized as current, former, or never smokers. Alcohol consumption status was categorized as binge, moderate, or never drinkers. Binge drinker status was defined as a current drinker with alcohol consumption of greater than 25 grams of alcohol per day for men and 15 grams per day for women. Moderate drinker status was defined as a current drinker with alcohol consumption of less than or equal to 25 grams per day for men and 15 grams per day for women. Never drinker status was those who self-reported never having had regular alcohol consumption. Physical activity was defined by 2 questions—“exercise or not at present?” and “exercised or not in the past?.” If the participants answered “Yes” to “exercise or not at present?” regardless of past exercise status, the physical activity was defined as “current.” If the answers were “No” for both questions, the physical activity was defined as “never.” If the participants answered “No” for “exercise or not at present?” and “Yes” for “exercised or not in the past?,” the physical activity status was defined as “former.” Dietary pattern was categorized as unfavorable, intermediate, or favorable by a simplified healthy eating index based on intake frequency of 5 food categories including fruits, vegetables, fish, bean products, and tea, which were demonstrated to be associated with cognitive function [18,19]. A 3-point scale question was used to measure the current intake frequency of each food group: “always or almost every day,” “sometimes or occasionally,” or “rarely or never.” Those 3 terms received a score of 2, 1, or 0, respectively, with higher scores indicating higher consumption. The scores of the intake of the 5 foods were summed and categorized into 3 categories: unfavorable: 0 to 4; intermediate: 5 to 6; and favorable: 7 to 10. Totally, 34.6% of the participants have missing value in body mass index (BMI) because height was not measured before the 2005 CLHLS survey. We used body weight instead of BMI to build the healthy lifestyle score and included BMI in the sensitivity analysis. Logistic regression model with penalized splines evaluated nonlinear associations of body weight with cognitive impairment [20]; 2 weight cutoffs were identified (weight less than 38 kg or higher than 50 kg) above and below, in which there was no significant increase in the magnitude of odds ratio for cognitive impairment (). We assigned 0, 1, or 2 points for each group of the five 3-group lifestyle factors with higher score indicating a healthier lifestyle. The healthy lifestyle score was the sum of the scores of these 5 health-related factors ranging from 0 to 10. Three healthy lifestyle score cutoffs were identified (healthy: 8 to 10, intermediate: 6 to 7, and unhealthy: <6); among each cutoff, in which there was no significant change in the multitude of hazard ratio (HR) for mortality ().

Assessment of cognitive function

The cognitive function of CLHLS participants was assessed by the Chinese version of the MMSE through a home-based interview, which includes 24 items, covering 7 subscales including orientation (4 points for time orientation and 1 point for place orientation); naming foods (naming as many kinds of food as possible in 1 minute, 7 points); registration of 3 words (3 points); attention and calculation (mentally subtracting 3 iteratively from 20, 5 points); copy a figure (1 point); recall (delayed recall of the 3 words mentioned above, 3 points); and language (2 points for naming objectives, 1 point for repeating a sentence, and 3 points for listening and following directions). The MMSE score ranges from 0 to 30. Higher scores represent a better cognitive function. The validity and reliability of this Chinese MMSE has been verified in several previous studies [21,22]. Consistent with previous studies [23], because a high proportion of our participants did not have formal education (approximately 70%), cognitive impairment was defined as an MMSE score of less than 18.

Individual-level covariates

During each interview, the assessors measured a range of demographic, behavioral, and socioeconomic covariates. Following the previous studies, we consider potential confounders, including age, sex, ethnicity (Han versus others), residence (rural versus urban), main occupation before age 60 (nonmanual versus manual), marital status (currently married and living with spouse versus widowed, separated, divorced, or never married), education background (years of schooling: none versus ≥1 years of schooling), activity of daily living (need any assistance in bathing/dressing/toileting/transferring/eating/continence: impaired versus not impaired), and 7 kinds of self-reported diseases (chronic obstructive pulmonary disease [COPD], tuberculosis, all-cause cancer, diabetes, hypertension, stroke, and cardiovascular disease). All self-reported information was collected through face-to-face home interview by trained research staff members. Interviewees were encouraged to answer as many questions as possible. If they were unable to answer questions, a close family member or another proxy, such as a primary caregiver, provided answers [24].

Statistical analysis

The development of the statistical analysis plan is described in S2 Text. Selected characteristics were presented as mean and standard deviation (SD) (continuous variables) or frequency distribution (categorical variable) by APOE phenotype (APOE ε4 carriers versus noncarriers). ANOVA for continuous variables and chi-squared tests for categorical variables were applied to test the significance levels of the differences. The association between healthy lifestyle, APOE phenotype, and cognitive function was assessed using multivariable logistic regression. The model adjusted for age, sex, residency, education level and marital status, activity of daily living, and 7 kinds of self-reported diseases. In subgroup analyses, we examined whether the associations of cognitive impairment with lifestyle profiles differed by APOE ε4 genotypes in the multivariable-adjusted logistic regression model. The significance of multiplicative interactions was tested by cross product terms in the models. A 2-tailed P value of less than 0.05 was considered statistically significant. We conducted 9 sensitivity analyses to check the robustness of the results, and the methodology details were included in S1 Text. The sensitivity analyses were carried out (1) using the longitudinal cognitive decline as the outcome to reduce the bias related to the cross-sectional design; and (2) using different MMSE cutoff scores (lower than 16, 21, or 25) to define cognitive impairment. The cutoff of 25 was normally the definition of cognitive impairment used in the younger population [23]. The cutoff of 16 and 21 was near our definition (lower than 18). Additionally, we adopted cutoff scores based on education level, which is widely accepted and used in China to define cognitive impairment (<18 for those without formal education, <21 for those with 1 to 6 years of education, and <25 for those with more than 6 years of education) to make the outcome (cognitive impairment) more interpretable [25,26]; (3) incorporating blood pressure and diabetes into the lifestyle score to build a modifiable factor score to make the score more replicable with other well-established lifestyle scores such as Cardiovascular Health Metric [27] or Pooled Cohort Equations [28] and using this score to reproduce the analysis; and (4) mapping the MMSE score to Clinical Dementia Rating (CDR) (MMSE score: 30 [CDR stage: 0], MMSE score: 26 to 29 [CDR stage: 0.5], MMSE score: 21 to 25 [CDR stage: 1], MMSE score: 11 to 20 [CDR stage: 2], and MMSE score 0 to 10 [CDR stage: 3]) [29] and using the CDR as outcome and ordinal logistics model to reproduce the analysis for increasing the statistical power. We also applied linear regression with MMSE score as outcome to reproduce our analysis, (5) excluding those who died within 2 years of the baseline surveys; (6) excluding the participants with an MMSE score equal to 0; (7) excluding the participants with deafness or blindness for those participants may have a low MMSE score because of the deafness or blindness; (8) using BMI to build the healthy lifestyle score instead of body weight, and the cutoff points were identified by a logistics regression model with penalized splines (0 point: <18 kg/m2, 1 point: 18 to 21 kg/m2, 2 points: >21 kg/m2) (); and (9) repeating the analyses using Poisson regression models to further add the statistical power. The analyses were performed using STATA version 14.0 (Stata, College Station, Texas, United States of America) and R (version 3.61).

Results

Baseline characteristics of participants

Characteristics of the study sample are presented in . A total of 6,160 participants were included after excluding 239 participants that lacked genetic (N = 133), cognitive (N = 51), or lifestyle (N = 59) assessment. The total study sample comprised 1,076 APOE ε4 carriers (17.5%) and 5,084 APOE ε4 noncarriers (82.5%) with an average age of 90.1 ± 7.2 years, and among them, 1,267 (24.9%) had cognitive impairment. Participants with APOE ε4 genotype were more likely to be younger (mean age: 89.8 versus 90.8) and men (men: 45.4% versus 41.7%) (). a Numbers shown are N (%) unless otherwise noted. b ANOVA for continuous variables and chi-squared tests for categorical variables were applied to test the significance levels of the differences between APOE ɛ4 carriers and noncarriers. c Manual worker includes professional, technical, governmental, institutional, or managerial personnel. Nonmanual worker includes those agriculture, forest, animal husbandry and fishery worker, industrial worker, commercial or service worker, military personnel, housework, and others. d Activity of daily living: assessed by 6 self-reported questions: “Do you need assistance in bathing/dressing/toileting/transferring/eating/continence?”. Impaired activity of daily living was defined as if the participants answered “Yes” for any of those questions. e Cognitive impairment: Cognitive impairment was defined by an MMSE score of less than 18. f Dietary pattern: categorized by a simplified healthy eating index (unfavorable: 0–4; intermediate: 5–6; and favorable: 7–10). g Healthy lifestyle profile: categorized by a healthy lifestyle score [healthy (8–10), intermediate (6–7), and unhealthy lifestyle (0–5)]. APOE, apolipoprotein E; IQR, interquartile range; MMSE, Mini-Mental State Examination; SD, standard deviation.

Single lifestyle factors’ association with cognitive impairment

The associations of smoking, alcohol consumption, dietary pattern, physical activity, and body weight with cognitive impairment were presented in . Current physical activity and a favorable dietary pattern was significantly associated with lower odds of cognitive impairment compared with their counterparts after adjusting for a group of covariates (current versus never physical activity: odds ratio [OR]: 0.66, 95% confidence interval [CI]: 0.55, 0.79, P < 0.001; favorable versus unfavorable dietary pattern: OR: 0.42, 95% CI: 0.35, 0.51, P < 0.001). No significant association was found between smoking, alcohol consumption, body weight, and cognitive impairment in the adjusted model. * Cognitive impairment: Cognitive impairment was defined by an MMSE score of less than 18. ** Model adjusted for age, sex, residence, education level, marital status, APOE genotype, lifestyle factors (smoking, alcohol consumption, physical activity, body weight, and dietary pattern), activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, cancer, diabetes, hypertension, stroke, and cardiovascular disease). APOE, apolipoprotein E; CI, confidence interval; COPD, chronic obstructive pulmonary disease; MMSE, Mini-Mental State Examination; OR, odds ratio.

APOE ε4 genotype and lifestyle profiles’ associations with cognitive impairment

presents the association between APOE genotypes, lifestyle profiles, and cognitive function. In the multivariable logistic regression, the APOE ε4 noncarriers had 17% lower odds of cognitive impairment (95% CI: 1% to 31%, P = 0.042) compared with those carrying the ε4 allele. Compared with those with an unhealthy lifestyle, participants with intermediate and healthy lifestyle were associated with 28% (95% CI: 16%, 38%, P < 0.001) and 55% (95% CI: 44%, 64%, P < 0.001) lower odds of cognitive impairment in the multivariable-adjusted model. In the longitudinal analysis, similar associations of cognitive decline with lifestyle profile and APOE genotypes were observed in the adjusted model () (healthy versus unhealthy lifestyle: OR: 0.72, 95% CI: 0.54, 0.95, P = 0.033; APOE ε4 noncarrier versus carrier: OR: 0.75, 95% CI: 0.60, 0.94, P = 0.027).

Associations* of cognitive impairment** with APOE ε4 genotype and lifestyle profiles.

*Model adjusted for age, sex, residence, education level, marital status, APOE genotype, lifestyle profile, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, cancer, diabetes, hypertension, stroke, and cardiovascular disease). **Cognitive impairment: cognitive impairment was defined by an MMSE score of less than 18. APOE, apolipoprotein E; CI, confidence interval; COPD, chronic obstructive pulmonary disease; MMSE, Mini-Mental State Examination.

Subgroup analyses and sensitivity analyses

presents the associations between lifestyle profiles and cognitive impairment stratified by APOE ε4 genotype. In the subgroup analyses by APOE genotype, among APOE ε4 noncarriers, the odds of cognitive impairment in participants with a healthy lifestyle was lower than that in those with an unhealthy lifestyle (OR: 0.47, 95% CI: 0.37 to 0.60, P < 0.001) (). In the model among APOE ε4 carriers, the pattern was similar (panel B), and the interaction between APOE genotype and lifestyle profiles was not significant (P = 0.62, P = 0.30). In the model including all participants and a variable indicating the joint classification of lifestyle profile and APOE ε4 genotype, we could observe the same dose–response relationship between lifestyle groups and cognitive impairment among both APOE ε4 carriers and noncarriers ().

Associations* between cognitive impairment** and lifestyle profiles stratified by APOE genotype.

*Models adjusted for age, sex, residence, education level, marital status, APOE genotype, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, cancer, diabetes, hypertension, stroke, and cardiovascular disease). **Cognitive impairment: cognitive impairment was defined by an MMSE score of less than 18. APOE, apolipoprotein E; CI, confidence interval; COPD, chronic obstructive pulmonary disease; MMSE, Mini-Mental State Examination. In supplemental analyses, we presented the associations between single lifestyle factors and cognitive impairment stratified by APOE genotype in . The associations of cognitive impairment with smoking, alcohol consumption, physical activity, dietary pattern, and body weight did not vary by APOE genotype (all Ps > 0.05). Those sensitivity analyses showed that the associations between lifestyle profiles and cognitive impairment were consistent with our main analysis after (1) excluding deaths in 2 years after the baseline survey (N = 4,947, ); (2) excluding 122 participants with deafness and blindness (N = 6,038, ); (3) excluding 505 participants with an MMSE score equal to 0 (N = 5,655, ); (4) using BMI to build the healthy lifestyle score instead of body weight (N = 4107, ); (5) defining cognitive impairment with different MMSE cutoff scores (16, 21, and 25) and using the education-adjusted outcome (); (6) adding blood pressure and diabetes in the lifestyle score (); (7) using ordinal logistics model and mapping the MMSE score to CDR as outcome and using linear regression with MMSE score as outcome (); and (8) using Poisson regression to estimate the risk ratios ()

Discussion

In this cross-sectional study of the Chinese oldest old (aged 80 years or older), we assessed the association between APOE ε4 genotype, lifestyle profiles, and cognitive impairment. Our results suggested that the odds of cognitive impairment was 17% (95% CI: 1% to 30%) lower among those APOE ε4 noncarriers (versus carriers) and 52% lower among those with healthy (versus unhealthy) lifestyle after controlling for sociodemographic, disability, and a number of chronic diseases. In addition, a healthier lifestyle was associated with lower odds of cognitive impairment regardless of APOE genotype. Our study adds evidence to the relationships of gene and lifestyle with cognition among the oldest old. This population group are the fastest-growing segment of society and have a high risk of developing cognitive impairment with a prevalence up to 40% [30,31]. Such increasing number of older people with cognitive impairment and dementia have major clinical and financial consequences for patients, their families, and society [32]. However, effective interventions were reluctant to target on this special population group considering the benefit could be relatively small due to comparatively short expected life years than that among younger peers. In line with some of the previous studies that also found the lifestyle intervention could be beneficial for older adults in high-income countries [33], our study demonstrated that lifestyle intervention to the oldest old population could be beneficial for cognition throughout the whole life cycle, regardless of their APOE genotype. As the oldest old population group is rapidly growing in China as well as in other countries that have experienced population aging, cognitive outcomes in this age group may benefit from public health interventions including lifestyle modification programs. Another defining feature of our study is that we examined lifestyle as a profile instead of single risk factors. Although there is growing evidence supporting the effect of individual lifestyle factors on cognition [13,34-36], few studies have explored the joint effects of healthy lifestyle profiles especially among the oldest old. Consistent with previous reports [8,9], the present analysis supported the hypothesis of a combined effect of healthy lifestyle on cognition and further extend this to the oldest old population. Of the 5 factors we examined, only 2 were found to be significant in multivariable models on single factors only. Nevertheless, the combined profile—defined based on prior studies [5,8-10]—was significantly associated with cognition, with healthier participants having less than half of the odds of cognitive impairment compared with the unhealthy ones. This result demonstrated the strengths of examining lifestyle factors as a group as they often cluster together and may create multiplicative instead of additive effects. In our study, a significant association between APOE ε4 genotype and cognitive impairment was found, similar to a previous study among 425 Chinese elderly with an average age of 83 years [37]. However, another study among 1,445 Chinese elderly (average age: 71.95 ± 5.65) reported a lack of association between APOE genotype and cognitive function. One reason accounting for the inconsistency may be the differences in the ages of the study populations. In a study including 10,371 Koreans aged 45 to 74 years, carrying APOE ε4 allele was associated with lower MMSE scores only among those participants between 65 and 74 years old [38]. Additionally, a similar phenomenon was also found among the other races. In the study using the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium data, which included 543,949 European participants from 31 cohorts, the magnitude of the association between rs10119 in the APOE region and worse cognitive ability increased with the mean age of each cohort. The effect was close to zero in younger cohorts, aged 55 to 60 years, and most pronounced in the oldest old [39]. Taken together, our finding of a positive association between APOE genotype and cognition among individuals 80 years or older may suggest that the effect of APOE genotype on cognitive function might be cumulative. To be more specific, with APOE ε4 allele’s negative influence on neuronal functioning, ε4 carriers may have a higher speed of neuronal cell loss which is irreversible [40]. Accordingly, during the early life stage, the difference in cognitive function between APOE ε4 carriers and noncarriers may not be significant, while as people age, APOE ε4 carriers may have a lower average cognitive function compared with noncarriers of the same age due to the cumulative damage of ε4 allele on neurons. On the other hand, in our study, ε4 noncarriers were slightly older than carriers, suggesting that there might be a survival effect from the ε4 genotype. If the more susceptible die earlier, there may be an attenuation of the relationships under study as people age. These complex relationships need to be further examined in future studies. Additionally, our findings suggest that the development of AD risk stratification tools may benefit from the incorporation of the role of age in considering the association between APOE genotype and cognition. The interaction between APOE genotype and individual lifestyle factors or lifestyle as a profile is controversial [11-13,23,24]. In a study with 14 years of follow-up and an average age at baseline of 69 years old [8], healthy lifestyle profiles only showed its benefits among APOE ε4 noncarriers. Yet another study from the UK Biobank (N = 196,383 average age: 64.1 years and median follow-up 8.2 years) found that favorable lifestyle profile was related to lower dementia risk regardless of the genetic dementia risk measured by a polygenetic risk score including APOE genotype [9]. Consistent with the UK Biobank study, we found that the association between lifestyle profiles and cognitive function did not vary by APOE ε4 genotype. These findings provide an optimistic perspective that a healthy lifestyle was still associated with lower odds of cognitive impairment among those with high genetic dementia risk. Our results suggest that although genetic risk cannot be modified from the genome, modifiable lifestyle factors are associated with cognitive outcomes independent of genetic risk even at a very advanced age. It may be beneficial for physicians to recommend that the oldest old adopt a healthier lifestyle to improve cognitive outcomes regardless of current cognitive function and genetic AD risk. Additionally, our results, if further validated by longitudinal studies among the oldest old population, may suggest that lifestyle interventions among those oldest old with high genetic risk may be still effective in promoting better cognitive performance. Methodologic strengths of this study include a large sample size of the oldest old and the combination of 5 lifestyle factors instead of single factors. Our study also has several limitations: (1) it has a cross-sectional design and cannot evaluate changes in lifestyles or establish causality. However, our results were robust to adjustment of a number of indicators such as diseases and activity of daily living. Nevertheless, prospective studies on the incidence of cognitive impairment are warranted; (2) the lifestyle measurements were self-reported thus nonspecific, and some measurements such as total cholesterol or high-density lipoproteins included in the established lifestyle metrics were not available in CLHLS [41]. However, the categorization based on the summary score has been shown to be a simple and powerful tool to classify people into different lifestyle groups, also those 5 factors were regarded as common behavior factors; (3) we used the Chinese version of MMSE to measure cognition, which is not a clinical diagnosis for cognitive impairment [42,43]. However, it is a validated instrument in population-based studies; (4) the CI of the association between APOE genotype and cognitive impairment was wide. But, its association was demonstrated in prior studies with large sample size [44]. Of note, the magnitude of the association between APOE ε4 genotype and cognition in our study was low (about 20% increased odds) compared to some other studies that found up to 3-fold higher risks [45]. Although our finding of the low magnitude was consistent with other studies conducted among adults 80 years and older [46], this rather weak association could partly explain why a healthy lifestyle “outweighed” genetic makeup in relation to cognitive impairment; and (5) lastly, because our study sample only came from the oldest old in China from the CLHLS with their unique characteristics such as low body weight compared to populations of high-income countries, its generalizability may be limited.

Conclusions

In summary, we found that the APOE genotype and lifestyle profiles were independently associated with cognitive impairment. In addition, the association between lifestyle profile and cognition was independent of APOE genotype among Chinese oldest old. Our results, corroborated by other interventional studies on lifestyle modification and cognitive function [47], support the importance of maintaining healthy lifestyle throughout the life course, even among the oldest old.

STROBE checklist.

STROBE, Strengthening the Reporting of Observational Studies in Epidemiology. (DOCX) Click here for additional data file.

Methods section for the sensitivity analysis.

(DOCX) Click here for additional data file.

Development of the statistical analysis plan.

(DOCX) Click here for additional data file.

Copy of the survey questions (used variables marked as red).

(DOC) Click here for additional data file.

The adjusted OR of cognitive impairment of body weight and BMI in logistics regression models with penalized splines.

Adjustment: age at baseline, sex, residency, education level, APOE genotype, lifestyle factors (smoking, alcohol consumption, dietary pattern, and physical activity), activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, all-cause cancer, diabetes, hypertension, stroke, and cardiovascular disease). The logistics regression models with penalized splines evaluated nonlinear associations of cognitive impairment with weight and BMI; 2 cutoffs were identified (weight: less than 38 kg or higher than 50 kg, BMI: lower than 18 kg/m2 or higher than 21 kg/m2) above and below, in which there was no significant increase in the multitude of OR for cognitive impairment. APOE, apolipoprotein E; BMI, body mass index; COPD, chronic obstructive pulmonary disease; OR, odds ratio. (DOCX) Click here for additional data file.

The adjusted OR of cognitive impairment for lifestyle score and modifiable factor score in logistics regression models with penalized splines.

Adjustment: age at baseline, sex, residency, education level, APOE genotype, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, all-cause cancer, diabetes, hypertension, stroke, and cardiovascular disease). The logistics regression models with penalized splines evaluated nonlinear associations of cognitive impairment with lifestyle score and modifiable factor score; 2 cutoffs were identified (lifestyle score: less than 6 or higher than 7; modifiable factor score: less than 5 or higher than 8) above and below, in which there was no significant increase in the multitude of OR for cognitive impairment. APOE, apolipoprotein E; COPD, chronic obstructive pulmonary disease; OR, odds ratio. (DOCX) Click here for additional data file.

Association between single lifestyle factors and cognitive impairment stratified by APOE genotype.

Cognitive impairment: Cognitive impairment was defined by MMSE scores less than 18. Adjustment: age at baseline, sex, residency, education level, APOE genotype, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, all-cause cancer, diabetes, hypertension, stroke, and cardiovascular disease). APOE, apolipoprotein E; COPD, chronic obstructive pulmonary disease; MMSE, Mini-Mental State Examination. (DOCX) Click here for additional data file.

Associations of cognitive decline with APOE ε4 genotype and lifestyle profiles (N = 3,136 with 1,564 decline).

Model was adjusted for age at baseline, baseline MMSE score, sex, residency, education level, marital status, APOE genotype, lifestyle profile, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, all-cause cancer, diabetes, hypertension, stroke, and cardiovascular disease). APOE, apolipoprotein E; COPD, chronic obstructive pulmonary disease; MMSE, Mini-Mental State Examination. (DOCX) Click here for additional data file.

Sensitivity analysis: associations of cognitive function with APOE ε4 genotype and lifestyle profiles excluding the participants dead in 2 years after baseline survey (N = 4,947).

Model was adjusted for age at baseline, sex, residency, education level, marital status, APOE genotype, lifestyle profile, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, all-cause cancer, diabetes, hypertension, stroke, and cardiovascular disease). APOE, apolipoprotein E; COPD, chronic obstructive pulmonary disease. (DOCX) Click here for additional data file.

Sensitivity analysis: associations of cognitive function with APOE ε4 genotype and lifestyle profiles excluding the participants with deafness or blindness (N = 6,038).

Model was adjusted for age at baseline, sex, residency, education level, marital status, APOE genotype, lifestyle profile, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, all-cause cancer, diabetes, hypertension, stroke, and cardiovascular disease). APOE, apolipoprotein E; COPD, chronic obstructive pulmonary disease. (DOCX) Click here for additional data file.

Sensitivity analysis: associations of cognitive function with APOE ε4 genotype and lifestyle profiles excluding the participants with MMSE score equal to 0 (N = 5,655).

Model was adjusted for age at baseline, sex, residency, education level, marital status, APOE genotype, lifestyle profile, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, all-cause cancer, diabetes, hypertension, stroke and cardiovascular disease). APOE, apolipoprotein E; COPD, chronic obstructive pulmonary disease; MMSE, Mini-Mental State Examination. (DOCX) Click here for additional data file.

Sensitivity analysis: associations of cognitive function with APOE ε4 genotype and lifestyle profiles using BMI instead of body weight to build the healthy lifestyle score (N = 4,126).

Model was adjusted for age at baseline, sex, residency, education level, marital status, APOE genotype, lifestyle profile, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, all-cause cancer, diabetes, hypertension, stroke, and cardiovascular disease). APOE, apolipoprotein E; BMI, body mass index; COPD, chronic obstructive pulmonary disease. (DOCX) Click here for additional data file.

Sensitivity analysis: associations of cognitive function with APOE ε4 genotype and lifestyle profiles defining cognitive impairment with different MMSE cutoff and using the education-adjusted outcome.

Model was adjusted for age at baseline, sex, residency, education level, marital status, APOE genotype, lifestyle profile, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, all-cause cancer, diabetes, hypertension, stroke, and cardiovascular disease). APOE, apolipoprotein E; COPD, chronic obstructive pulmonary disease; MMSE, Mini-Mental State Examination. (DOCX) Click here for additional data file.

Sensitivity analysis: associations of cognitive function with APOE ε4 genotype and lifestyle profiles by adding blood pressure and diabetes in the lifestyle score.

Model was adjusted for age at baseline, sex, residency, education level, marital status, APOE genotype, lifestyle profile, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, all-cause cancer, diabetes, hypertension, stroke, and cardiovascular disease). APOE, apolipoprotein E; COPD, chronic obstructive pulmonary disease. (DOCX) Click here for additional data file.

Sensitivity analysis: associations of cognitive function with APOE ε4 genotype and lifestyle profiles using ordinal logistics model and mapping the MMSE score to CDR as outcome/using linear regression with MMSE score as outcome.

Model was adjusted for age at baseline, sex, residency, education level, marital status, APOE genotype, lifestyle profile, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, all-cause cancer, diabetes, hypertension, stroke, and cardiovascular disease). APOE, apolipoprotein E; CDR, Clinical Dementia Rating; COPD, chronic obstructive pulmonary disease; MMSE, Mini-Mental State Examination. (DOCX) Click here for additional data file.

Sensitivity analysis: associations of cognitive function with APOE ε4 genotype and lifestyle profiles using Passion regression.

Model was adjusted for age at baseline, sex, residency, education level, marital status, APOE genotype, lifestyle profile, activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, all-cause cancer, diabetes, hypertension, stroke, and cardiovascular disease). APOE, apolipoprotein E; COPD, chronic obstructive pulmonary disease. (DOCX) Click here for additional data file.
Table 1

Baseline characteristics of the 6,160 participants by APOE ɛ4 genotype.

CharacteristicsaTotal sample N = 6,160APOE ɛ4 genotype
Carrier N = 1,076Noncarrier N = 5,084P valueb
Age, mean ± SD90.1 ± 7.289.8 ± 7.090.8 ± 7.3<0.001
Sex0.028
    Men2,609 (42.3)488 (45.4)2,121 (41.7)
    Women3,551 (57.6)588 (54.6)2,963 (58.3)
Residence0.91
    Urban2,126 (34.5)373 (34.7)1,753 (34.5)
    Rural4,034 (65.5)703 (65.3)3,331 (65.5)
Main occupation before age 60c0.68
    Nonmanual378 (6.8)69 (6.4)309 (6.1)
    Manual5,782 (93.9)1,007 (93.6)4,775 (93.9)
Education background (school years)0.27
    None (0)4,271 (69.3)731 (67.9)3,540 (69.7)
    Ever (≥1)1,889 (30.7)345 (32.1)1,488 (29.3)
Marital status0.38
    Married (spouse alive)1,380 (22.4)252 (23.4)1,128 (22.2)
    Others4,778 (77.6)824 (76.6)3,954 (77.8)
Ethnicity0.74
    Han5,739 (93.1)1,000 (92.9)4,739 (93.2)
    Others (minority)421 (6.8)76 (7.1)345 (6.8)
Impaired activity of daily livingd0.36
    Yes1,428 (23.2)238 (23.4)1,190 (22.2)
    No4,732 (76.8)838 (76.6)3,894 (77.8)
MMSE score, mean ± SD21.4 ± 9.221.5 ± 9.121.3 ± 9.20.46
Cognitive impairmente0.60
    With1,537 (25.0)270 (25.1)1,267 (24.9)
    Without4,623 (75.0)806 (74.9)3,817 (75.1)
Smoking0.25
    Current979 (15.9)189 (17.5)790 (15.5)
    Former864 (14.0)145 (13.5)719 (14.1)
    Never4,317 (70.1)742 (69.0)3,575 (70.3)
Alcohol consumption0.57
    Binge drink717 (11.6)132 (12.3)585 (11.5)
    Moderate drink432 (7.0)69 (6.4)363 (7.1)
    Never drink5,011 (81.3)875 (81.3)4,136 (81.4)
Regular physical activity0.97
    Current1,712 (27.8)297 (27.6)1,415 (27.8)
    Former454 (7.4)77 (7.2)377 (7.4)
    Never3,994 (64.8)702 (65.2)3,292 (64.8)
Dietary patternf0.13
    Unfavorable1,817 (29.5)292 (27.6)1,525 (30.0)
    Intermediate2,592 (41.5)476 (44.2)2,116 (41.6)
    Favorable1,751 (28.4)308 (28.6)1,443 (28.4)
Weight (kg)0.56
    <38989 (16.1)180 (16.7)809 (15.9)
    38–502,960 (48.1)507 (47.1)2,453 (48.2)
    >502,211 (35.9)389 (36.2)1,822 (35.8)
Healthy lifestyle profileg0.49
    Unhealthy2,317 (37.6)408 (37.9)1,909 (37.5)
    Intermediate2,617 (42.5)461 (42.8)2,156 (42.4)
    Healthy1,226 (19.9)207 (19.2)1,019 (20.0)

a Numbers shown are N (%) unless otherwise noted.

b ANOVA for continuous variables and chi-squared tests for categorical variables were applied to test the significance levels of the differences between APOE ɛ4 carriers and noncarriers.

c Manual worker includes professional, technical, governmental, institutional, or managerial personnel. Nonmanual worker includes those agriculture, forest, animal husbandry and fishery worker, industrial worker, commercial or service worker, military personnel, housework, and others.

d Activity of daily living: assessed by 6 self-reported questions: “Do you need assistance in bathing/dressing/toileting/transferring/eating/continence?”. Impaired activity of daily living was defined as if the participants answered “Yes” for any of those questions.

e Cognitive impairment: Cognitive impairment was defined by an MMSE score of less than 18.

f Dietary pattern: categorized by a simplified healthy eating index (unfavorable: 0–4; intermediate: 5–6; and favorable: 7–10).

g Healthy lifestyle profile: categorized by a healthy lifestyle score [healthy (8–10), intermediate (6–7), and unhealthy lifestyle (0–5)].

APOE, apolipoprotein E; IQR, interquartile range; MMSE, Mini-Mental State Examination; SD, standard deviation.

Table 2

Association between single lifestyle factor and cognitive impairment. *

Independent variableLogistic regression, OR of cognitive impairment (95% CI)
Unadjusted modelP valueAdjusted model**P value
Smoking
    CurrentReferenceReference
    Former1.12 (0.85, 1.47)0.430.98 (0.74, 1.31)0.89
    Never1.18 (0.95, 1.49)0.131.14 (0.90, 1.43)0.51
Alcohol consumption
    Binge drinkingReferenceReference
    Moderate drinking0.73 (0.52, 1.03)0.0810.79 (0.55, 1.14)0.21
    Never drinking1.14 (0.92, 1.41)0.251.08 (0.86, 1.37)0.90
Physical activity
    NeverReferenceReference
    Former1.13 (0.91, 1.41)0.710.87 (0.66, 1.11)0.25
    Current0.46 (0.40, 0.55)<0.0010.66 (0.55, 0.79)<0.001
Dietary pattern
    UnfavorableReferenceReference
    Intermediate0.69 (0.60, 0.79)<0.0010.66 (0.57, 0.77)<0.001
    Favorable0.44 (0.38, 0.52)<0.0010.42 (0.35, 0.51)<0.001
Body weight (kg)
    <38ReferenceReference
    38–500.63 (0.54. 0.74)<0.0010.96 (0.80, 1.15)0.59
    >500.51 (0.44, 0.62)<0.0010.88 (0.70, 1.09)0.21

* Cognitive impairment: Cognitive impairment was defined by an MMSE score of less than 18.

** Model adjusted for age, sex, residence, education level, marital status, APOE genotype, lifestyle factors (smoking, alcohol consumption, physical activity, body weight, and dietary pattern), activity of daily living, and 7 kinds of self-reported disease (COPD, tuberculosis, cancer, diabetes, hypertension, stroke, and cardiovascular disease).

APOE, apolipoprotein E; CI, confidence interval; COPD, chronic obstructive pulmonary disease; MMSE, Mini-Mental State Examination; OR, odds ratio.

  46 in total

1.  Free knot splines for logistic models and threshold selection.

Authors:  F Bessaoud; J P Daures; N Molinari
Journal:  Comput Methods Programs Biomed       Date:  2005-01       Impact factor: 5.428

2.  Forecasting the global burden of Alzheimer's disease.

Authors:  Ron Brookmeyer; Elizabeth Johnson; Kathryn Ziegler-Graham; H Michael Arrighi
Journal:  Alzheimers Dement       Date:  2007-07       Impact factor: 21.566

3.  Risk of atherosclerotic cardiovascular disease by cardiovascular health metric categories in approximately 1 million patients.

Authors:  Jamal S Rana; Jennifer Y Liu; Howard H Moffet; Andrew J Karter; Khurram Nasir; Matthew D Solomon; Marc G Jaffe; Andrew P Ambrosy; Alan S Go; Stephen Sidney
Journal:  Eur J Prev Cardiol       Date:  2020-02-07       Impact factor: 7.804

4.  Cognitive impairment and mortality among the oldest-old Chinese.

Authors:  Ruopeng An; Gordon G Liu
Journal:  Int J Geriatr Psychiatry       Date:  2016-02-18       Impact factor: 3.485

5.  Mediterranean diet and cognitive function in older age.

Authors:  Cécilia Samieri; Francine Grodstein; Bernard A Rosner; Jae H Kang; Nancy R Cook; Joann E Manson; Julie E Buring; Walter C Willett; Olivia I Okereke
Journal:  Epidemiology       Date:  2013-07       Impact factor: 4.822

Review 6.  The role of apolipoprotein E in Alzheimer's disease.

Authors:  Jungsu Kim; Jacob M Basak; David M Holtzman
Journal:  Neuron       Date:  2009-08-13       Impact factor: 17.173

7.  Mapping scores onto stages: mini-mental state examination and clinical dementia rating.

Authors:  Robert Perneczky; Stefan Wagenpfeil; Katja Komossa; Timo Grimmer; Janine Diehl; Alexander Kurz
Journal:  Am J Geriatr Psychiatry       Date:  2006-02       Impact factor: 4.105

8.  APOE ɛ4 polymorphism and cognitive deficit among the very old Chinese veteran men without dementia.

Authors:  Che-Sheng Chu; Ti Lu; Shih-Jen Tsai; Cheng-Jee Hong; Heng-Liang Yeh; Albert C Yang; Mu-En Liu
Journal:  Neurosci Lett       Date:  2014-06-02       Impact factor: 3.046

9.  Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function.

Authors:  Gail Davies; Max Lam; Sarah E Harris; Joey W Trampush; Michelle Luciano; W David Hill; Saskia P Hagenaars; Stuart J Ritchie; Riccardo E Marioni; Chloe Fawns-Ritchie; David C M Liewald; Judith A Okely; Ari V Ahola-Olli; Catriona L K Barnes; Lars Bertram; Joshua C Bis; Katherine E Burdick; Andrea Christoforou; Pamela DeRosse; Srdjan Djurovic; Thomas Espeseth; Stella Giakoumaki; Sudheer Giddaluru; Daniel E Gustavson; Caroline Hayward; Edith Hofer; M Arfan Ikram; Robert Karlsson; Emma Knowles; Jari Lahti; Markus Leber; Shuo Li; Karen A Mather; Ingrid Melle; Derek Morris; Christopher Oldmeadow; Teemu Palviainen; Antony Payton; Raha Pazoki; Katja Petrovic; Chandra A Reynolds; Muralidharan Sargurupremraj; Markus Scholz; Jennifer A Smith; Albert V Smith; Natalie Terzikhan; Anbupalam Thalamuthu; Stella Trompet; Sven J van der Lee; Erin B Ware; B Gwen Windham; Margaret J Wright; Jingyun Yang; Jin Yu; David Ames; Najaf Amin; Philippe Amouyel; Ole A Andreassen; Nicola J Armstrong; Amelia A Assareh; John R Attia; Deborah Attix; Dimitrios Avramopoulos; David A Bennett; Anne C Böhmer; Patricia A Boyle; Henry Brodaty; Harry Campbell; Tyrone D Cannon; Elizabeth T Cirulli; Eliza Congdon; Emily Drabant Conley; Janie Corley; Simon R Cox; Anders M Dale; Abbas Dehghan; Danielle Dick; Dwight Dickinson; Johan G Eriksson; Evangelos Evangelou; Jessica D Faul; Ian Ford; Nelson A Freimer; He Gao; Ina Giegling; Nathan A Gillespie; Scott D Gordon; Rebecca F Gottesman; Michael E Griswold; Vilmundur Gudnason; Tamara B Harris; Annette M Hartmann; Alex Hatzimanolis; Gerardo Heiss; Elizabeth G Holliday; Peter K Joshi; Mika Kähönen; Sharon L R Kardia; Ida Karlsson; Luca Kleineidam; David S Knopman; Nicole A Kochan; Bettina Konte; John B Kwok; Stephanie Le Hellard; Teresa Lee; Terho Lehtimäki; Shu-Chen Li; Christina M Lill; Tian Liu; Marisa Koini; Edythe London; Will T Longstreth; Oscar L Lopez; Anu Loukola; Tobias Luck; Astri J Lundervold; Anders Lundquist; Leo-Pekka Lyytikäinen; Nicholas G Martin; Grant W Montgomery; Alison D Murray; Anna C Need; Raymond Noordam; Lars Nyberg; William Ollier; Goran Papenberg; Alison Pattie; Ozren Polasek; Russell A Poldrack; Bruce M Psaty; Simone Reppermund; Steffi G Riedel-Heller; Richard J Rose; Jerome I Rotter; Panos Roussos; Suvi P Rovio; Yasaman Saba; Fred W Sabb; Perminder S Sachdev; Claudia L Satizabal; Matthias Schmid; Rodney J Scott; Matthew A Scult; Jeannette Simino; P Eline Slagboom; Nikolaos Smyrnis; Aïcha Soumaré; Nikos C Stefanis; David J Stott; Richard E Straub; Kjetil Sundet; Adele M Taylor; Kent D Taylor; Ioanna Tzoulaki; Christophe Tzourio; André Uitterlinden; Veronique Vitart; Aristotle N Voineskos; Jaakko Kaprio; Michael Wagner; Holger Wagner; Leonie Weinhold; K Hoyan Wen; Elisabeth Widen; Qiong Yang; Wei Zhao; Hieab H H Adams; Dan E Arking; Robert M Bilder; Panos Bitsios; Eric Boerwinkle; Ornit Chiba-Falek; Aiden Corvin; Philip L De Jager; Stéphanie Debette; Gary Donohoe; Paul Elliott; Annette L Fitzpatrick; Michael Gill; David C Glahn; Sara Hägg; Narelle K Hansell; Ahmad R Hariri; M Kamran Ikram; J Wouter Jukema; Eero Vuoksimaa; Matthew C Keller; William S Kremen; Lenore Launer; Ulman Lindenberger; Aarno Palotie; Nancy L Pedersen; Neil Pendleton; David J Porteous; Katri Räikkönen; Olli T Raitakari; Alfredo Ramirez; Ivar Reinvang; Igor Rudan; Reinhold Schmidt; Helena Schmidt; Peter W Schofield; Peter R Schofield; John M Starr; Vidar M Steen; Julian N Trollor; Steven T Turner; Cornelia M Van Duijn; Arno Villringer; Daniel R Weinberger; David R Weir; James F Wilson; Anil Malhotra; Andrew M McIntosh; Catharine R Gale; Sudha Seshadri; Thomas H Mosley; Jan Bressler; Todd Lencz; Ian J Deary
Journal:  Nat Commun       Date:  2018-05-29       Impact factor: 14.919

10.  Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population.

Authors:  Silvan Licher; Shahzad Ahmad; Hata Karamujić-Čomić; Trudy Voortman; Maarten J G Leening; M Arfan Ikram; M Kamran Ikram
Journal:  Nat Med       Date:  2019-08-26       Impact factor: 53.440

View more
  4 in total

1.  Effect of berry-based supplements and foods on cognitive function: a systematic review.

Authors:  Negar Bonyadi; Neda Dolatkhah; Yaghoub Salekzamani; Maryam Hashemian
Journal:  Sci Rep       Date:  2022-02-25       Impact factor: 4.379

Review 2.  Gene-environment interactions in Alzheimer disease: the emerging role of epigenetics.

Authors:  Lucia Migliore; Fabio Coppedè
Journal:  Nat Rev Neurol       Date:  2022-09-30       Impact factor: 44.711

3.  An exploratory pilot study on the involvement of APOE, HFE, C9ORF72 variants and comorbidities in neurocognitive and physical performance in a group of HIV-infected people.

Authors:  Isabella Zanella; Eliana Zacchi; Chiara Fornari; Benedetta Fumarola; Melania Degli Antoni; Daniela Zizioli; Eugenia Quiros-Roldan
Journal:  Metab Brain Dis       Date:  2022-03-30       Impact factor: 3.655

4.  Association of Body Mass Index and Plant-Based Diet with Cognitive Impairment among Older Chinese Adults: A Prospective, Nationwide Cohort Study.

Authors:  Fang Liang; Jialin Fu; Gabrielle Turner-McGrievy; Yechuang Wang; Nan Qiu; Kai Ding; Jing Zeng; Justin B Moore; Rui Li
Journal:  Nutrients       Date:  2022-07-29       Impact factor: 6.706

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.